CARGO Therapeutics, Inc. (CRGX)
NASDAQ: CRGX · IEX Real-Time Price · USD
15.83
-0.17 (-1.06%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Company Description
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients.
The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.
It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets.
The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022.
CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.
CARGO Therapeutics, Inc.
| Country | United States |
| Founded | 2021 |
| IPO Date | Nov 10, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 123 |
| CEO | Ms. Gina Chapman |
Contact Details
Address: 835 Industrial Road, Suite 400 San Carlos, California 94070 United States | |
| Phone | 650-499-8950 |
| Website | cargo-tx.com |
Stock Details
| Ticker Symbol | CRGX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001966494 |
| CUSIP Number | 14179K101 |
| ISIN Number | US14179K1016 |
| Employer ID | 84-4080422 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Gina Chapman | President, Chief Executive Officer and Director |
| Dr. Crystal L. Mackall M.D. | Co-Founder |
| Dr. Shishir Gadam Ph.D. | Chief Technical Officer |
| Dr. Robbie Majzner M.D. | Founder and Chair of Scientific Advisory Board |
| Nancy Goodman J.D. | Founder |
| Dr. Louai Labanieh | Founder |
| Anup Radhakrishnan | Chief Financial Officer, Secretary and Chief Business Officer |
| Dr. Corinne D. Epperly M.D., M.P.H. | Chief Operating Officer |
| Faisal Shawwa M.B.A. | Senior Vice President of Finance and Accounting |
| Dr. Michael Ports Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 27, 2024 | EFFECT | Notice of Effectiveness |
| Jun 27, 2024 | 424B3 | Prospectus |
| Jun 17, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jun 4, 2024 | 8-K | Current Report |
| May 28, 2024 | 8-K | Current Report |
| May 14, 2024 | 10-Q | Quarterly Report |
| May 14, 2024 | 8-K | Current Report |
| Apr 24, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 24, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 15, 2024 | 8-K | Current Report |